• Recent company disclosures provide the main operational, financial or project milestones.
Paradigm is developing injectable pentosan polysulfate sodium, known as iPPS and branded Zilosul, as a potential disease-modifying therapy for knee osteoarthritis. The ambition is important: most osteoarthritis treatments manage symptoms such as pain, whereas a disease-modifying therapy would aim to alter the underlying progression …
Racura Oncology, which changed its name from Race Oncology, is developing bisantrene, historically known as Zantrene, as an anti-cancer agent with a distinctive dual profile: potential activity against cancer alongside a protective effect against the cardiotoxicity that some chemotherapies cause. Its lead advanced program, …
Cambium Bio (ASX:CMB), based in Sydney and formerly Regeneus, developsBiologicsfor ophthalmology and tissue repair. Its lead asset is reportedly an eye-drop biologic derived from platelet and secretome technology, targeting severe dry-eye and ocular-surface disease, alongside a broader regenerative platform. As a clinical-stage, pre-commercial company, …
Audeara, based in Brisbane, operates in hearing health and personalised audio. Its products include headphones and earbuds that run an in-app hearing test and tailor sound to the user's individual hearing profile, and it is increasingly licensing its signal-processing and artificial-intelligence algorithms, covering areas …
The 9.40-cent final is a single half-yearly payment; the 18.40-cent figure is the relevant full-year number and is fully franked, adding meaningful after-tax value for eligible Australian shareholders. The 13% lift in the annual dividend reflects bothEarningsgrowth and management confidence in the durability of …
The 37.0-cent final is a single fully franked payout and should not be annualised in isolation; the relevant full-year figure is 69.0 cents. Even so, on a share price measured in the hundreds of dollars the running yield sits far below 1%, making Pro …
The 63-cent final is unfranked, so shareholders should not expect franking credits attached to this distribution --- a long-standing feature of Sonic given that most of its profit is generated in Germany, the United States, Switzerland and other offshore markets. The payment matches the …
The 10.90-cent final is fully franked, adding franking credits for eligible Australian shareholders on top of the cash payment. It is the larger of Medibank's two half-yearly dividends and lifts the full-year payout by 6.7%. Because Medibank pays semi-annually, the 10.90-cent figure is a …
The 9.25-cent final dividend is the larger of ACL's two half-year payments and lifts the full-year total to 13.0 cents, up from the prior year. Based on ACL's consistent history, the dividend is fully franked, adding franking credits for eligible holders. At about $2.80 …